Mhawi A Amir, Peel Sean Alexander Fitzgerald, Fok Tommy Chi-On, Clokie Cameron Malcolm Lang
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.
J Craniofac Surg. 2007 May;18(3):497-503. doi: 10.1097/scs.0b013e318052e2b1.
Bioimplants containing bone morphogenetic proteins (BMP) such as demineralized bone matrix (DBM) are used clinically to repair bone defects because of their ability to stimulate bone regeneration. Because of handling issues, DBM granules are often combined with an inert carrier, which reduces the DBM content to 40% or less by volume. Recently, Accell DBM100 (Accell, IsoTis OrthoBiologics, Irvine, CA) has been developed, which uses processed DBM as the carrier, resulting in a DBM content of 100%. The purpose of this investigation was to evaluate the use of Accell for bone defect healing.Forty-two athymic male rats were divided into three groups. Bilateral 5 mm calvarial defects were created in each animal. In group 1, one defect was filled with Accell and the other defect was left unfilled (control). In group 2, one defect was filled with OP-1 putty (recombinant human BMP-7 and type I collagen), and the other was left unfilled. In group 3, one defect was filled with Accell and the other with OP-1. Animals were sacrificed at 4 and 8 weeks, postoperatively. Specimens were analyzed by histomorphometry to evaluate bone regeneration quantitatively. Accell and OP-1 both induced significantly more bone at 4 and 8 weeks compared with the unfilled contralateral defects. OP-1-filled defects produced significantly more total reparative tissue (bone + marrow) compared with Accell (P < 0.01); however, the increase in new bone did not reach significance at either time (P = 0.06 at 4 wk; P = 0.10 at 8 wk). In conclusion, these results suggest that Accell DBM100 will be useful in repairing craniofacial bone defects clinically.
含有骨形态发生蛋白（BMP）的生物植入物，如脱矿骨基质（DBM），因其能够刺激骨再生，在临床上被用于修复骨缺损。由于操作问题，DBM颗粒常与惰性载体结合，这使得DBM的体积含量降低至40%或更低。最近，Accell DBM100（Accell，IsoTis OrthoBiologics，加利福尼亚州欧文市）已被研发出来，它使用经过处理的DBM作为载体，使得DBM含量达到100%。本研究的目的是评估Accell在骨缺损愈合中的应用。42只雄性无胸腺大鼠被分为三组。在每只动物的颅骨上制造双侧5毫米的骨缺损。在第1组中，一个缺损用Accell填充，另一个缺损不填充（对照）。在第2组中，一个缺损用OP-1油灰（重组人BMP-7和I型胶原蛋白）填充，另一个不填充。在第3组中，一个缺损用Accell填充，另一个用OP-1填充。术后4周和8周处死动物。通过组织形态计量学分析标本以定量评估骨再生。与未填充的对侧缺损相比，Accell和OP-1在4周和8周时均诱导出明显更多的骨。与Accell相比，用OP-1填充的缺损产生的总修复组织（骨+骨髓）明显更多（P<0.01）；然而，新骨的增加在两个时间点均未达到显著水平（4周时P = 0.06；8周时P = 0.10）。总之，这些结果表明Accell DBM100在临床上对修复颅面骨缺损将是有用的。
